No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Samsung Bioepis Successfully Opposes Grant of Janssen’s AU Ustekinumab Patent Application
On 3 October 2025, IP Australia delivered its decision in Samsung Bioepis’ opposition to the grant of Janssen’s AU2019346134 relating to a method of treating ulcerative colitis with Stelara® (ustekinumab).